List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8072166/publications.pdf Version: 2024-02-01



LAUDIE H SEHN

#	Article	IF	CITATIONS
1	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances, 2022, 6, 533-543.	5.2	77
2	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Advances, 2022, 6, 1651-1660.	5.2	14
3	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2022, 40, 481-491.	1.6	160
4	Limited-stage diffuse large B-cell lymphoma. Blood, 2022, 139, 822-834.	1.4	22
5	CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. Blood, 2022, 139, 2737-2746.	1.4	60
6	A prognostic model integrating PETâ€derived metrics and image texture analyses with clinical risk factors from GOYA. EJHaem, 2022, 3, 406-414.	1.0	6
7	Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review. Leukemia and Lymphoma, 2022, , 1-4.	1.3	0
8	Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. British Journal of Haematology, 2022, 198, 684-692.	2.5	4
9	A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies. Current Oncology, 2022, 29, 3940-3949.	2.2	7
10	Revising the Treatment Pathways in Lymphoma: New Standards of Care—How Do We Choose?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 629-642.	3.8	2
11	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncology, The, 2022, 23, 1055-1065.	10.7	119
12	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood, 2021, 137, 2196-2208.	1.4	18
13	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 267-278.e10.	0.4	8
14	Primary mediastinal large Bâ€cell lymphoma. EJHaem, 2021, 2, 23-24.	1.0	0
15	Outcome of relapsed and refractory nodular lymphocyteâ€predominant Hodgkin lymphoma: a North American analysis. British Journal of Haematology, 2021, 192, 560-567.	2.5	9
16	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Advances, 2021, 5, 1483-1489.	5.2	17
17	Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2021, 384, 842-858.	27.0	388
18	Single-nucleotide FcÎ ³ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Advances, 2021, 5, 2935-2944.	5.2	10

#	Article	IF	CITATIONS
19	Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Advances, 2021, 5, 2945-2957.	5.2	7
20	Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma. Journal of Nuclear Medicine, 2021, , jnumed.121.262324.	5.0	2
21	Impact of Disease Extent and Distribution on Outcomes in Stage II Follicular Lymphoma Treated with Curative-Intent Radiation Therapy. Blood, 2021, 138, 2431-2431.	1.4	0
22	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia, 2020, 34, 522-532.	7.2	26
23	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2020, 38, 155-165.	1.6	488
24	Validation of a simplified international prognostic score (IPSâ€3) in patients with advancedâ€stage classic Hodgkin lymphoma. British Journal of Haematology, 2020, 189, 122-127.	2.5	9
25	Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood, 2020, 136, 1006-1010.	1.4	15
26	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. Journal of Hematology and Oncology, 2020, 13, 71.	17.0	82
27	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. Leukemia and Lymphoma, 2020, 61, 2492-2496.	1.3	0
28	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Medicine, 2020, 26, 577-588.	30.7	46
29	Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada. Blood, 2020, 136, 13-15.	1.4	0
30	Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. Blood, 2020, 136, 18-19.	1.4	0
31	Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC). Blood, 2020, 136, 33-34.	1.4	0
32	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood, 2019, 134, 761-764.	1.4	77
33	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 2019, 3, 2013-2021.	5.2	40
34	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 481-484.	2.4	10
35	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood, 2019, 133, 919-926.	1.4	89
36	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. Blood, 2019, 134, 2845-2845.	1.4	1

#	Article	IF	CITATIONS
37	Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma. Blood, 2019, 134, 1285-1285.	1.4	9
38	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood, 2019, 134, 401-401.	1.4	18
39	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer, 2018, 93, 57-68.	2.8	90
40	Double hit lymphoma: do we need a †double hit' of intensive therapy?. Leukemia and Lymphoma, 2018, 59, 1767-1768.	1.3	3
41	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. Journal of Clinical Oncology, 2018, 36, 2259-2266.	1.6	107
42	Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. Current Oncology Reports, 2018, 20, 103.	4.0	9
43	Editor's introduction. Best Practice and Research in Clinical Haematology, 2018, 31, 185-186.	1.7	0
44	Management of relapsed/refractory DLBCL. Best Practice and Research in Clinical Haematology, 2018, 31, 209-216.	1.7	91
45	A tale of two antibodies: obinutuzumab <i>versus</i> rituximab. British Journal of Haematology, 2018, 182, 29-45.	2.5	123
46	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia and Lymphoma, 2017, 58, 324-332.	1.3	32
47	Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Haematologica, 2017, 102, e199-e202.	3.5	4
48	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	2.8	65
49	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica, 2017, 102, 1413-1423.	3.5	39
50	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact. Blood, 2017, 129, 2760-2770.	1.4	112
51	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Annals of Hematology, 2017, 96, 253-259.	1.8	22
52	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leukemia and Lymphoma, 2017, 58, 711-714.	1.3	7
53	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20â€year British Columbia Cancer Agency experience. British Journal of Haematology, 2017, 176, 234-240.	2.5	20
54	Site of central nervous system (CNS) relapse in patients with diffuse large B ell lymphoma (DLBCL) by the CNSâ€iPI risk model. British Journal of Haematology, 2017, 179, 508-510.	2.5	26

#	Article	IF	CITATIONS
55	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2017, 35, 3529-3537.	1.6	333
56	Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the <scp>BC</scp> Cancer Agency Centre for Lymphoid Cancer. British Journal of Haematology, 2016, 172, 757-768.	2.5	38
57	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology, 2016, 34, 3150-3156.	1.6	313
58	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. Journal of Clinical Oncology, 2016, 34, 2493-2500.	1.6	56
59	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. Journal of the National Cancer Institute, 2016, 108, djw257.	6.3	56
60	Novel agents in follicular lymphoma: choosing the best target. Hematology American Society of Hematology Education Program, 2016, 2016, 284-292.	2.5	3
61	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood, 2016, 127, 2182-2188.	1.4	145
62	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B ell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	2.5	34
63	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. Haematologica, 2016, 101, e411-e414.	3.5	11
64	Diffuse Large B-Cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1179-1194.	2.2	6
65	The Increasing Complexity of Aggressive B-cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, xiii-xiv.	2.2	0
66	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2016, 17, 1081-1093.	10.7	297
67	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 276-282.	1.3	14
68	Cell of origin of transformed follicular lymphoma. Blood, 2015, 126, 2118-2127.	1.4	91
69	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood, 2015, 126, 2646-2649.	1.4	64
70	Rituximab with highâ€dose methotrexate in primary central nervous system lymphoma. American Journal of Hematology, 2015, 90, 1149-1154.	4.1	41
71	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood, 2015, 125, 22-32.	1.4	445
72	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 341-348.	0.4	39

LAURIE H SEHN

#	Article	IF	CITATIONS
73	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 2015, 33, 2848-2856.	1.6	334
74	Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncology, The, 2015, 16, 704-715.	10.7	272
75	Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treatment Reviews, 2015, 41, 784-792.	7.7	52
76	Outcome prediction by extranodal involvement, IPI, Râ€IPI, and NCCNâ€IPI in the PET/CT and rituximab era: A <scp>D</scp> anish– <scp>C</scp> anadian study of 443 patients with diffuseâ€large <scp>B</scp> â€cell lymphoma. American Journal of Hematology, 2015, 90, 1041-1046.	4.1	71
77	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 ⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. Journal of Clinical Oncology, 2015, 33, 3467-3474.	1.6	149
78	Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 3978-3978.	1.4	17
79	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. Blood, 2015, 126, 3950-3950.	1.4	0
80	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica, 2014, 99, 1343-1349.	3.5	79
81	<scp>CD</scp> 30 expression in <i>de novo</i> diffuse large Bâ€cell lymphoma: a populationâ€based study from British Columbia. British Journal of Haematology, 2014, 167, 608-617.	2.5	84
82	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 2014, 123, 837-842.	1.4	693
83	<scp>MYC</scp> and <scp>BCL</scp> 2 protein expression predicts survival in patients with diffuse large <scp>B</scp> â€cell lymphoma treated with rituximab. British Journal of Haematology, 2014, 165, 382-391.	2.5	157
84	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood, 2014, 123, 3567-3573.	1.4	76
85	Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma. Cancer Journal (Sudbury, Mass), 2012, 18, 421-426.	2.0	21
86	International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. Journal of Clinical Oncology, 2012, 30, 3383-3388.	1.6	171
87	Reply to L. Wannesson et al. Journal of Clinical Oncology, 2012, 30, 336-337.	1.6	0
88	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood, 2012, 119, 5118-5125.	1.4	145
89	Treatment and Outcomes of Primary Breast Lymphoma. Clinical Breast Cancer, 2012, 12, 412-419.	2.4	46
90	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2012, 120, 2290-2296.	1.4	53

#	Article	IF	CITATIONS
91	Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S82-S91.	2.0	17
92	Limited $\hat{a} \in s$ tage diffuse large B $\hat{a} \in c$ ell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. Cancer, 2012, 118, 4156-4165.	4.1	49
93	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-9.	2.5	44
94	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-409.	2.5	48
95	CD30 Expression in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1558-1558.	1.4	5
96	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. Blood, 2012, 120, 303-303.	1.4	29
97	A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood, 2012, 120, 56-56.	1.4	11
98	A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis. Blood, 2012, 120, 1586-1586.	1.4	0
99	Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era. Blood, 2012, 120, 1602-1602.	1.4	Ο
100	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood, 2011, 117, 7070-7078.	1.4	168
101	Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology, 2011, 29, 1452-1457.	1.6	197
102	Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2011, 29, 3396-3401.	1.6	33
103	Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. Blood, 2011, 118, 269-269.	1.4	18
104	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. Blood, 2011, 118, 780-780.	1.4	3
105	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica, 2010, 95, 96-101.	3.5	63
106	A decade of R-CHOP. Blood, 2010, 116, 2000-2001.	1.4	17
107	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. Value in Health, 2010, 13, 703-711.	0.3	25
108	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (Râ€CHOP). British Journal of Haematology, 2010, 148, 235-244.	2.5	38

#	Article	IF	CITATIONS
109	Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology, 2010, 28, 1017-1024.	1.6	57
110	Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leukemia and Lymphoma, 2010, 51, 1-10.	1.3	53
111	Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. Blood, 2010, 116, 1751-1751.	1.4	4
112	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. Blood, 2010, 116, 417-417.	1.4	2
113	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, 2010, 116, 2005-2005.	1.4	2
114	The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 4129-4129.	1.4	0
115	Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma. Blood, 2010, 116, 800-800.	1.4	0
116	Early detection of patients with poor risk diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2009, 50, 1744-1747.	1.3	18
117	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica, 2009, 94, 423-427.	3.5	53
118	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood, 2009, 113, 3773-3780.	1.4	133
119	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines Blood, 2009, 114, 408-408.	1.4	28
120	Alemtuzumab in clinical practice: A British Columbia experience. Leukemia and Lymphoma, 2008, 49, 218-226.	1.3	12
121	Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 5165-5169.	1.6	333
122	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. Journal of Clinical Oncology, 2008, 26, 447-454.	1.6	159
123	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 2008, 111, 5509-5514.	1.4	93
124	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2008, 112, 3425-3433.	1.4	130
125	Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 479-479.	1.4	2
126	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2007, 48, 1102-1109.	1.3	63

#	Article	IF	CITATIONS
127	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2007, 109, 1857-1861.	1.4	1,193
128	Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood, 2007, 109, 4171-4173.	1.4	98
129	FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan Blood, 2007, 110, 213-213.	1.4	3
130	Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone Blood, 2007, 110, 787-787.	1.4	16
131	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma Blood, 2007, 110, 790-790.	1.4	14
132	Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP Blood, 2007, 110, 1559-1559.	1.4	1
133	Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach. Clinical Lymphoma and Myeloma, 2006, 7, S14-S19.	1.4	4
134	Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma. Hematology American Society of Hematology Education Program, 2006, 2006, 295-302.	2.5	40
135	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level Blood, 2006, 108, 2739-2739.	1.4	0
136	Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R) Blood, 2006, 108, 2027-2027.	1.4	0
137	Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology, 2005, 23, 5027-5033.	1.6	874
138	Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP) Blood, 2005, 106, 492-492.	1.4	7
139	Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology, 2005, 19, 26-34.	0.5	29
140	Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization Blood, 2004, 104, 1407-1407.	1.4	9
141	New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Annals of Lymphoma, 0, 3, 10-10.	4.5	11
142	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia and Lymphoma, 0, , 1-16.	1.3	1